FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-028									
Estimated average burden										

	Check this box if no longer subject to
)	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP hours per response: 0.5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Schobel Alexander Mark</u>						2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST]										heck all app	onship of Reportin Ill applicable) Director Officer (give title		10% O	wner
_	(Last) (First) (Middle) C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE						f Earlie 019	st Trar	nsact	tion (Mo	onth/E	Day/Year)		^ below	v) ``	ion/T	Other (specify below) on/Tech Officer			
(Street) WARRE (City)	N N.	J (07059 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Lir	ne) X Form Form	,				
		Tab	le I - Nor	n-Deriv	ative	Sec	curiti	es Ac	cqu	ired,	Disp	osed	of, o	r Ber	neficia	lly Owne	d			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Insti			Dispose	rities Acquired (A) ed Of (D) (Instr. 3, 4			Benefi Owned	ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
										Code	v	Amount		(A) or (D)	Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock 03/31/					/2019	2019				M ⁽¹⁾		329		A	\$0	1,0	27,971		D	
Common Stock 03/31/					/2019					F ⁽²⁾		263	B D S		\$6.9	1 1,027,708		D		
		Т		Derivat (e.g., p												y Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	ransaction code (Instr.		of		Exp	Pate Exe piration I pnth/Day	Date		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exe	e ercisable		piration ite	Title		Amount or Number of Shares	per				
Restricted Stock	\$0	03/31/2019			M ⁽¹⁾			329	03/	/31/2019		(3)	Comi		329	\$0	1,649		D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 2. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability.
- 3. There are no expiration dates on RSUs.

Remarks:

/s/ Robert Arnold, as Attorney-04/01/2019 **In-Fact**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.